Bial Introduces Awareness and Education Initiative in Support of World Parkinson’s Day
Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, has announced the launch of a major global awareness initiative titled “Dialogues with Parkinson’s” to mark World Parkinson’s Day. The campaign is designed as a year-long effort to improve communication between people living with Parkinson’s disease, their caregivers, and healthcare professionals, with the ultimate goal of enhancing early diagnosis, treatment outcomes, and overall disease management.
Developed in collaboration with Parkinson’s Europe, the initiative integrates both scientific insights and real-world patient experiences. This dual approach reflects a growing recognition that effective disease management depends not only on clinical advancements but also on meaningful, informed dialogue among all stakeholders involved in patient care.
Parkinson’s disease is one of the fastest-growing neurological conditions globally, affecting more than 10 million people today. Projections suggest that this number could rise dramatically to 25 million by 2050, driven by aging populations and improved diagnostic capabilities. While the condition is often associated with older adults, a significant proportion of cases—estimated between 10% and 20%—are diagnosed in individuals under the age of 50. These early-onset cases frequently present unique challenges, as symptoms may be subtler and less easily recognized, leading to delays in diagnosis and intervention.
João Norte, Vice President of Global Marketing, Access & Patient Value at Bial, highlighted the persistent misconceptions surrounding the disease. He noted that many people still perceive Parkinson’s as a condition that only affects older individuals, which can result in younger patients overlooking early warning signs. Additionally, a general lack of awareness about the disease’s diverse symptoms often prevents individuals from seeking timely medical advice.
According to Norte, these factors can significantly impact patient outcomes. Delayed diagnosis may limit the effectiveness of available treatments and hinder the ability to tailor therapeutic strategies during the early stages of the disease, when interventions are most beneficial. As a result, improving awareness and communication has become a critical priority in the fight against Parkinson’s disease.
The “Dialogues with Parkinson’s” campaign seeks to address these challenges by positioning communication as a central component of clinical care. By encouraging patients, caregivers, and healthcare providers to “speak the same language,” the initiative aims to foster more productive and transparent conversations throughout the care journey. This includes discussions about symptoms, treatment expectations, medication adherence, and the emotional and psychological aspects of living with the disease.
A key feature of the campaign is the development of a range of digital tools and educational resources. These include practical guides, symptom checklists, and conversation prompts designed to help individuals better articulate their experiences and concerns. For patients, these tools can provide clarity and confidence when discussing symptoms with healthcare professionals. For clinicians, they offer structured ways to gather more comprehensive information and deliver personalized care.
One of the specific areas of focus within the campaign is improving awareness of “OFF episodes,” a common but often underreported aspect of Parkinson’s disease. OFF episodes occur when the effects of medication wear off, leading to the return or worsening of symptoms such as tremors, stiffness, and difficulty with movement. Recognizing and accurately describing these episodes is essential for optimizing treatment regimens, yet many patients struggle to communicate their experiences effectively.
By promoting better understanding of OFF episodes and other symptom fluctuations, the campaign aims to support earlier intervention and more precise treatment adjustments. This, in turn, can help improve quality of life for individuals living with Parkinson’s disease and reduce the overall burden of the condition.
In addition to supporting patients and healthcare providers, the initiative also seeks to enhance health literacy among the general public. By raising awareness about the early signs of Parkinson’s and challenging common misconceptions, the campaign encourages more people to seek medical evaluation when symptoms arise. This proactive approach is particularly important given the progressive nature of the disease, where early diagnosis can play a crucial role in slowing symptom progression and maintaining functional independence.
João Norte emphasized that the campaign reflects Bial’s broader commitment to creating value for patients beyond traditional drug development. He noted that the company aims to place patients at the center of its efforts, whether through educational initiatives or through ongoing research aimed at advancing new therapeutic options.
Indeed, Bial continues to invest heavily in research and development for Parkinson’s disease, with a particular focus on innovative therapies that address underlying disease mechanisms. One of the most promising candidates in its pipeline is BIA 28-6156, a first-in-class investigational drug targeting patients with a specific genetic variation in the glucocerebrosidase 1 (GBA1) gene. Mutations in this gene are known to increase the risk of developing Parkinson’s disease and are associated with more aggressive disease progression.
BIA 28-6156 has the potential to become a disease-modifying therapy, meaning it could go beyond symptom management to address the root causes of the condition. This represents a significant shift in the treatment paradigm, as current therapies primarily focus on alleviating symptoms rather than altering the course of the disease itself.
The drug is currently being evaluated in a Phase 2b clinical trial known as the ACTIVATE study. All participants in the trial have completed the full double-blind treatment period through week 78, marking an important milestone in the development process. Topline results from the study are expected to be released by the end of the first half of 2026, providing critical insights into the therapy’s safety and efficacy.
As the global burden of Parkinson’s disease continues to grow, initiatives like “Dialogues with Parkinson’s” highlight the importance of a comprehensive approach to care—one that combines scientific innovation with patient-centered communication and education. By addressing both the clinical and human dimensions of the disease, Bial and its partners aim to empower individuals, improve outcomes, and ultimately transform the way Parkinson’s disease is understood and managed worldwide.
About Bial
Bial is an innovation-driven pharmaceutical company dedicated to improving the health and lives of people worldwide. With a strong commitment to therapeutic innovation, Bial has established an ambitious R&D programme, consistently investing over 20% of its annual revenue in this area. The company focuses on two key areas with high unmet medical needs: neurosciences and rare diseases.
In Europe, Bial operates manufacturing facilities and an R&D centre at its headquarters in Portugal, and maintains subsidiaries in Spain, Germany, the United Kingdom, Italy, and Switzerland. In addition, Bial is present in the United States and selected emerging markets. As part of its international growth strategy, the company collaborates with established partners through strategic alliances and licensing agreements to expand access to its healthcare solutions.
Currently, Bial’s products are available in more than 50 countries, advancing its mission to pursue scientific excellence, mainly in neurosciences and rare diseases, delivering transformative medicines that empower patients’ lives.
Source Link:https://www.businesswire.com/
